Compare Ecopetrol SA (EC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Sana Biotechnology Inc — how do they compare? Ecopetrol SA trades at $16.93 (market cap $33.11B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Ecopetrol SA is far larger — about 39.6× Sana Biotechnology Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Sana Biotechnology Inc for 23 Days on average.
| EC | SANA | |
|---|---|---|
Market Cap | $33.11B | $836.71M |
Volume | 993,598 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $18.26 | $5.92 |
52-Week Low | $8.61 | $2.68 |
Typical Hold Time | 84 Days | 23 Days |
Enterprise Value | $61.36B | $749.96M |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 7.99 and EV/EBITDA of 4.04, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains solid profitability with 11.37% net margin and 17.67% ROE.
EC presents a mixed outlook with undervalued fundamentals against operational challenges. Investment opportunity lies in discounted valuation and potential stabilization under new leadership, but risks include persistent revenue decline, political interference, and negative cash flow trends. Analyst consensus remains cautious with 54.55% hold rating and $16.85 price target, slightly above current levels.
SANA Biotechnology trades at $2.72, down 1.09% with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with negative revenue, a net loss of $244.17 million in 2025, and negative cash flow. However, analyst sentiment remains positive with 82% buy ratings and recent conference presentations highlighting ongoing research in engineered cell therapies.
The outlook is highly speculative given the pre-revenue stage and substantial losses. Investment opportunity lies in the potential of SANA's biotechnology platform, but risks include cash burn, clinical trial outcomes, and competitive pressures. Wall Street maintains cautious optimism despite fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
